HepG2BD: A Novel and Versatile Cell Line with Inducible HDV Replication and Constitutive HBV Expression
Viruses · 2024
DOI: 10.3390/v16040532 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Matthieu Blanchet und 6 weiteren Autor:innen. Beteiligte Einrichtung: INRS-Centre Armand-Frappier Santé Biotechnologie, Laval, QC H7V 1B7, Canada. Hauptthemen laut MEDLINE: Hepatitis Delta Virus, Virus Replication, Hepatitis B virus. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Sciences and Engineering Research Council, Natural Sciences and Engineering Research Council of Canada, Replicor Inc..
Abstract (Originalsprache)
Individuals chronically infected with hepatitis B virus (HBV) and hepatitis Delta virus (HDV) present an increased risk of developing cirrhosis and hepatocellular carcinoma in comparison to HBV mono-infected individuals. Although HDV only replicates in individuals coinfected or superinfected with HBV, there is currently no in vitro model that can stably express both viruses simultaneously, mimicking the chronic infections seen in HBV/HDV patients. Here, we present the HepG2BD cell line as a novel in vitro culture system for long-term replication of HBV and HDV. HepG2BD cells derive from HepG2.2.15 cells in which a 2 kb HDV cDNA sequence was inserted into the adeno-associated virus safe harbor integration site 1 (AAVS1) using CRISPR-Cas9. A Tet-Off promoter was placed 5′ of the genomic HDV sequence for reliable initiation/repression of viral replication and secretion. HBV and HDV replication were then thoroughly characterized. Of note, non-dividing cells adopt a hepatocyte-like morphology associated with an increased production of both HDV and HBV virions. Finally, HDV seems to negatively interfere with HBV in this model system. Altogether, HepG2BD cells will be instrumental to evaluate, in vitro, the fundamental HBV–HDV interplay during simultaneous chronic replication as well as for antivirals screening targeting both viruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- INRS-Centre Armand-Frappier Santé Biotechnologie, Laval, QC H7V 1B7, Canada.
- Replicor Inc., Montréal, QC H4P 2R2, Canada.
- INSERM U1259, Université de Tours, 37032 Tours, France.
ORCID-Profile: Matthieu Blanchet, Léna Angelo, Camille Sureau, Andrew Vaillant
Förderung
- Natural Sciences and Engineering Research Council
- Natural Sciences and Engineering Research Council of Canada
- Replicor Inc.
- NSERC-Alliance
- Canada Graduate Scholarship—from the NSERC
Zitieren
APA
Blanchet, M., Angelo, L., Tétreault, Y., Khabir, M., Sureau, C., Vaillant, A., & Labonté, P. (2024). HepG2BD: A Novel and Versatile Cell Line with Inducible HDV Replication and Constitutive HBV Expression. Viruses. https://doi.org/10.3390/v16040532
Vancouver
Blanchet M, Angelo L, Tétreault Y, Khabir M, Sureau C, Vaillant A, et al. HepG2BD: A Novel and Versatile Cell Line with Inducible HDV Replication and Constitutive HBV Expression. Viruses. 2024. doi:10.3390/v16040532
BibTeX
@article{Blanchet2024,
author = {Blanchet, Matthieu and Angelo, Léna and Tétreault, Yasmine and Khabir, Marwa and Sureau, Camille and Vaillant, Andrew and Labonté, Patrick},
title = {HepG2BD: A Novel and Versatile Cell Line with Inducible HDV Replication and Constitutive HBV Expression},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16040532}
}
EUVIMED